Abstract:[Objective] To investigate the effects of phosphoinositide 3-kinase (PI3K) inhibitor LY294002 on the activity of PI3K/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway,as well as relevant biological behavioural alteration of gastric cancer MGC-803 cells.[Methods] Human gastric cancer MGC-803 cells were treated with LY294002 at 12.5,25,and 50 μmol/L (experimental groups).The mRNA expressions of key signal molecules in PI3K/AKT/mTOR signaling pathway including PTEN,PI3K,AKT,mTOR,P70S6K,and 4EBP,as well as related protein expressions,were detected by quantitative real-time PCR and Western blot,respectively.The growth-inhibiting effects of LY294002 on MGC-803 cells were detected by MTT assay.The effects on cell cycle and cell apoptosis were detected by flow cytometry.[Results] Compared with the control (DMSO) group,LY294002 significantly regulated the mRNA expressions of PI3K,PTEN,AKT,mTOR,4EBP,and P70S6K (P ＜0.05),and the mRNA expression levels of AKT,mTOR,4EBP,and P70S6K were declined with LY294002 concentration increasing.LY294002 significantly down-regulated the protein expression of AKT,p-mTOR,p-70S6K,and p-AKT,which showed a declining trend with LY294002 concentration increasing.The MTT assay results showed significant inhibiting effects of LY294002 on MGC-803 cells' proliferation as the proliferation rate increased with LY294002 concentration reducing (F=26.15,P＜0.01).The results of flow cytometry showed that the proportions of G0/G1 cells (F=358.594,P＜0.001) and the apoptosis rates (F=4.929,P＜0.05) of the LY294002 groups were higher than those of the control group in a dose-dependent manner.[Conclusion] LY294002 may inhibit the key signaling molecules of PI3K/AKT/mTOR signaling pathway in MGC-803 cells to varied degrees.The mRNA expressions of AKT,mTOR,4EBP,and P70S6K and related phosphorylated proteins show a declining pattern with LY294002 concentration increasing.Besides,LY294002 could decrease cell proliferation rate,change the proportion of cell cycle,and increase apoptosis rate.

Pp242 Suppresses Cell Proliferation, Metastasis, and Angiogenesis of Gastric Cancer Through Inhibition of the Pi3k/Akt/Mtor Pathway

Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics

PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway.

Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

Combination Of Mtor And Egfr Kinase Inhibitors Blocks Mtorc1 And Mtorc2 Kinase Activity And Suppresses The Progression Of Colorectal Carcinoma

The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.

OSI-027 Alleviates Oxaliplatin Chemoresistance in Gastric Cancer Cells by Suppressing P-gp Induction.

Targeting Mtorc2 Component Rictor Inhibits Cell Proliferation and Promotes Apoptosis in Gastric Cancer

Therapeutic Implications of Mtor Inhibitors in the Treatment of Gastric Cancer.

GL-1196 Suppresses the Proliferation and Invasion of Gastric Cancer Cells via Targeting PAK4 and Inhibiting PAK4-Mediated Signaling Pathways

Dual PI3K/mTOR Inhibitor PF-04979064 Regulates Tumor Growth in Gastric Cancer and Enhances Drug Sensitivity of Gastric Cancer Cells to 5-FU

Mammalian Target of Rapamycin Pathway Inhibition Enhances the Effects of 5-Aza-dc on Suppressing Cell Proliferation in Human Gastric Cancer Cell Lines

Targeting Inhibition of Extracellular Signal-Regulated Kinase Kinase Pathway with AZD6244 (ARRY-142886) Suppresses Growth and Angiogenesis of Gastric Cancer.

PPP2R2D, a Regulatory Subunit of Protein Phosphataseï¿½2a, Promotes Gastric Cancer Growth and Metastasis Via Mechanistic Target of Rapamycin Activation

The PI3K/mTOR Dual Inhibitor GSK458 Potently Impedes Ovarian Cancer Tumorigenesis and Metastasis

Effects of inhibiting PI3K/AKT/mTOR signaling pathway by LY294002 on gastric cancer MGC-803 cells

Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer

TIPRL, a Novel Tumor Suppressor, Suppresses Cell Migration, and Invasion Through Regulating AMPK/mTOR Signaling Pathway in Gastric Cancer

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Nab-Paclitaxel Antitumor Response in Experimental Gastric Cancer.

Lenvatinib acts on platelet‑derived growth factor receptor β to suppress the malignant behaviors of gastric cancer cells

Biochemical, Cellular, and in Vivo Activity of Novel Atp-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin